| Title |
Critical evaluation of latanoprostene bunod in the treatment of glaucoma
|
|---|---|
| Published in |
Clinical Ophthalmology, October 2016
|
| DOI | 10.2147/opth.s103985 |
| Pubmed ID | |
| Authors |
Giancarlo A Garcia, Philip Ngai, Sameh Mosaed, Ken Y Lin |
| Abstract |
Latanoprostene bunod (LBN) is a novel nitric oxide-donating prostaglandin F2α receptor agonist in clinical development for intraocular pressure lowering in open-angle glaucoma and ocular hypertension. Currently in Phase III clinical trials in the USA, European Union, and Japan, LBN has demonstrated promising efficacy while maintaining safety and tolerability. We review preclinical and clinical developmental efforts and evaluate the potential role of LBN monotherapy in the management of open-angle glaucoma and ocular hypertension. The current LBN clinical development program comprises eight trials, four of which have resulted in publication of complete methodology and outcomes. We additionally pool adverse events data to determine incidences across three pivotal studies. Evidence thus far indicates that LBN may be a safe and effective ocular hypotensive agent, although the potential neuroprotective effects and the impact on visual field loss remain to be evaluated. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 36 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 17% |
| Other | 4 | 11% |
| Professor > Associate Professor | 4 | 11% |
| Student > Master | 4 | 11% |
| Student > Doctoral Student | 3 | 8% |
| Other | 3 | 8% |
| Unknown | 12 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 25% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 11% |
| Nursing and Health Professions | 3 | 8% |
| Neuroscience | 2 | 6% |
| Computer Science | 1 | 3% |
| Other | 3 | 8% |
| Unknown | 14 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 July 2021.
All research outputs
#2,241,805
of 25,373,627 outputs
Outputs from Clinical Ophthalmology
#150
of 3,712 outputs
Outputs of similar age
#38,322
of 332,555 outputs
Outputs of similar age from Clinical Ophthalmology
#6
of 72 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,712 research outputs from this source. They receive a mean Attention Score of 4.9. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 332,555 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 72 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.